Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B™) In Alzheimer’S Disease
Reuters
03-11
March 11 (Reuters) - Longeveron Inc:: *LONGEVERON® ANNOUNCES NATURE MEDICINE PUBLICATION OF RESULTS OF PHASE 2A CLINICAL TRIAL EVALUATING LAROMESTROCEL (LOMECEL-B™) IN ALZHEIMER’S DISEASE *LONGEVERON INC - LAROMESTROCEL FIRST CELLULAR THERAPY TO RECEIVE FDA RMAT DESIGNATION FOR ALZHEIMER'S *LONGEVERON INC - TRIAL ACHIEVED PRIMARY SAFETY AND SECONDARY EFFICACY ENDPOINTS